Jefferies downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $70, after Stryker (SYK) announced an agreement to acquire Inari for $80 per share in cash. Given no product overlap, the firm sees little antitrust risk and expects the deal to close by end of Q1, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Morning Movers: Getty Images, Shutterstock surge following merger pact
- Inari Medical downgraded to Equal Weight from Overweight at Wells Fargo
- BofA goes to No Rating on Inari Medical after takeover deal
- Inari Medical downgraded to Market Perform from Outperform at William Blair
- Inari Medical price target raised at Piper after agreeing to be acquired